Can a specific protein signature in spinal fluid help identify amyotrophic lateral sclerosis?

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness and paralysis. Diagnosing ALS can be challenging because its early symptoms overlap with other conditions. Researchers are studying cerebrospinal fluid (CSF) — the fluid surrounding the brain and spinal cord — for protein biomarkers that could aid in earlier and more accurate diagnosis. Recent studies have identified specific protein patterns in CSF that may help distinguish ALS from other neurological diseases and healthy individuals.

What the research says

A cross-sectional CSF proteomic analysis used mass spectrometry to measure thousands of proteins in 87 ALS patients, 89 healthy controls, and 61 neurological controls ⁶. The study found 399 proteins that were significantly altered in ALS, including markers of neurodegeneration (NEFL, NEFM, UCHL1) and neuroinflammation (CHIT1, CHI3L1, CHI3L2) ⁶. Using machine learning, researchers identified a minimal five-protein panel (MB, ITLN1, YWHAG, FCGR3A, PGAM1) that accurately distinguished ALS patients from healthy controls, capturing disease-specific changes beyond general neurodegeneration ⁶. This signature also revealed prognostic candidates that changed with disease stage, such as complement proteins increasing as function declined ⁶.

Another study using network analysis of CSF proteomics in 101 individuals (including sporadic ALS, C9orf72, and SOD1 mutation carriers) identified both shared and unique protein differences across ALS subtypes ¹⁰. This was validated in a larger four-center cohort of 259 people, confirming that protein profiles vary between sporadic and familial forms of ALS ¹⁰. The Global Neurodegeneration Proteomics Consortium, which includes CSF and plasma samples from over 35,000 biofluid samples, is working to harmonize proteomic data across neurodegenerative diseases including ALS, aiming to improve biomarker discovery ⁹.

While these findings are promising, the protein signatures are still being validated in larger, diverse populations before they can be used routinely in clinical practice. The identified panels reflect underlying disease processes such as immune activation, synaptic dysfunction, and metabolic changes ⁶¹⁰.

What to ask your doctor

• Are there any ongoing studies or clinical trials at this center that are using CSF protein biomarkers for ALS diagnosis?
• How does the accuracy of a CSF protein panel compare with current diagnostic methods like electromyography (EMG) or MRI?
• Would a lumbar puncture to test CSF proteins be appropriate for my situation, and what are the risks?
• If I have a family history of ALS, could CSF proteomics help determine my risk or guide early monitoring?
• How might knowing my CSF protein profile influence treatment decisions or eligibility for clinical trials?